Sugi Predict

Sugi Predict / Compounds / Dexbudesonide

Dexbudesonide

Dexbudesonide

SCHEMBL8159866

CCC[C@@H]1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1.C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO

nearest known ligand 0.78

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

NR3C1

The experimentally established mechanism targets of Dexbudesonide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR3C1 known ✓ P04150 9/20 0.78
▸ HIF1A Q16665 6/20 0.78
▸ CYP3A4 P08684 5/20 0.78
▸ HSD17B10 Q99714 5/20 0.78
▸ PGR P06401 5/20 0.78
▸ NR3C2 P08235 3/20 0.78
▸ ABCB11 O95342 2/20 0.78
▸ AR P10275 2/20 0.78
▸ NFKB1 P19838 2/20 0.78
▸ SMN1; SMN2 Q16637 2/20 0.78
▸ ABCC3 O15438 1/20 0.78
▸ ABCC4 O15439 1/20 0.78
▸ IL5 P05113 1/20 0.78
▸ CHRM1 P11229 1/20 0.78
▸ MMP9 P14780 1/20 0.78
▸ THPO P40225 1/20 0.78
▸ LMNA P02545 1/20 0.78
▸ BLM P54132 1/20 0.78
▸ PMP22 Q01453 1/20 0.78
▸ NPSR1 Q6W5P4 1/20 0.78

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dexbudesonide SCHEMBL5655286 0.94 NR3C1 (0.88) NR3C1HIF1ACYP3A4HSD17B10PGR
Dexbudesonide SCHEMBL840948 0.93 HSD17B10 (0.72) NR3C1HIF1ACYP3A4HSD17B10PGR
Dexbudesonide SCHEMBL5504588 0.89 HIF1A (0.61) NR3C1HIF1ACYP3A4HSD17B10PGR
Dexbudesonide SCHEMBL8513617 0.89 NR3C1 (0.75) NR3C1HIF1ACYP3A4HSD17B10PGR
Budesonide SCHEMBL13871728 0.88 NR3C1 (1.00) NR3C1HIF1ACYP3A4HSD17B10PGR
Budesonide SCHEMBL12396756 0.88 NR3C1 (1.00) NR3C1HIF1ACYP3A4HSD17B10PGR
Budesonide SCHEMBL1130417 0.88 NR3C1 (1.00) NR3C1HIF1ACYP3A4HSD17B10PGR
Budesonide SCHEMBL21570019 0.88 NR3C1 (1.00) NR3C1HIF1ACYP3A4HSD17B10PGR
Budesonide SCHEMBL8056801 0.88 NR3C1 (1.00) NR3C1HIF1ACYP3A4HSD17B10PGR
Dexbudesonide SCHEMBL4095 0.88 NR3C1 (1.00) NR3C1HIF1ACYP3A4HSD17B10PGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021053167-A1 EXTRUDED DEPOT FORM FOR CONTROLLED ACTIVE SUBSTANCE RELEASE AMW GMBH (DE) 2021-03-25 — — WO disclosed
US-9988408-B2 Cytotoxic agents for conjugation to a cell binding molecule HANGZHOU DAC BIOTECH CO., LTD. (CN) 2018-06-05 — — US disclosed
US-20160207949-A1 NOVEL CYTOTOXIC AGENTS FOR CONJUGATION TO A CELL BINDING MOLECULE HANGZHOU DAC BIOTECH CO., LTD (CN) 2016-07-21 — — US disclosed
US-6068860-A FOR TOPICAL ADMINISTRATION COMPRISING FOSCARNET AND AN ANTIINFLAMMATORY GLUCOCORTICOID, WITH A CARRIER BASED ON GALACTOLIPIDS COMPRISING DIGALACTOSYLDIACYLGLYCEROLS, AND A POLAR SOLVENT; TREATING HERPES INFECTIONS ASTRA AKTIEBOLAG (SE) 2000-05-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160207949-A1 NOVEL CYTOTOXIC AGENTS FOR CONJUGATION TO A CELL BINDING MOLECULE PDCD5, CD4, PDCD6 NR3C1 2560/4885HIF1A 3332/4885CYP3A4 1923/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback